Item 5.07. Submission of Matters to a Vote of Security Holders.

Forte Biosciences, Inc. (the "Company") held its 2022 annual meeting of stockholders on June 1, 2022 (the "Annual Meeting"). Of the 14,761,261 shares of the Company's common stock outstanding as of the record date of April 22, 2022, 8,322,250 shares were represented at the Annual Meeting, either by proxy or by attending the meeting. The matters voted on at the Annual Meeting and the votes cast with respect to each such matter are set forth below:



1.  Election of Class II Directors. The following nominees were elected to serve
    as Class II directors, each to hold office until the Company's 2025 annual
    meeting of stockholders or until his or her respective successor has been
    duly elected and qualified:



Nominee                         Votes For       Votes Withheld       Broker Non-Votes
Steven Kornfeld                  3,366,874            1,581,706              3,373,670
Patricia Walker, M.D., Ph.D.     3,335,739            1,612,841              3,373,670



2.  Ratification of Appointment of Independent Registered Public Accounting Firm.
    The appointment of Mayer Hoffman McCann P.C. as the Company's independent
    registered public accounting firm for the fiscal year ending December 31,
    2022 was ratified based on the following results of voting:



Votes For   Votes Against   Abstentions   Broker Non-Votes
8,107,698      157,062        57,490             -



3.  Increase to the 2021 Equity Incentive Plan. The Company's stockholders
    approved the increase to the shares reserved under the Company's 2021 Equity
    Incentive Plan . The votes regarding the proposal were as follows:



Votes For   Votes Against   Abstentions   Broker Non-Votes
2,826,803     2,106,190       15,587         3,373,670

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses